JPRN-UMIN000006476招募中2 期
Multicenter phase II study of adding bevacizumab to oral S-1 therapy in advanced colorectal cancer who have failed prior oxaliplatin and irinotecan-based therapies - Phase II study of S-1 plus bevacizumab as the third-line therapy in advanced colorectal cancer (CCOG-1105; C3-03 study)
Cubu Clinical Oncology Group (CCOG)0 个研究点目标入组 30 人开始时间: 2011年10月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Uncontrolled infection. (2)Patient with symptomatic cardiovascular disease or asymptomatic disease but have been treated (>=Grade 2 according to NCI-CTCAE ver.4). History of myocardial infarction within a year. (3)Previous history of thoromboembolitic disease, or necessity for antithrombotic drug. (4)Severe lung disease. (5)Interstitial lung disease or pulmonary fibrosis. (6)Severe liver disease. (7)Severe renal failure, or urinary protein (more than 2+). (8)Previous history of severe drug-induced allergy (9)Intestinal bleeding, ileus, bowel obstruction or uncontrolled peptic ulcer. (10)Uncontrolled severe complications (DM, hypertension, diarrhea, et al.). (11)History of active double cancer. (12)Massive pleural effusion or ascites that required drainage. (13)Brain metastasis (14)Patient receiving surgical procedure or such as skin-open biopsy, trauma surgery, or other more intensive surgeries within 4 weeks or aspiration biopsy within a week. (15) Diathesis of bleeding (history of hemoptysis, including cavitation and/or necrosis in lung metastasis confirmed by imaging), coagulopathy. (16)Pregnant women, possibly pregnant women, wishing to become pregnant, and nursing mothers. (17)Not appropriate for the s
研究者
相似试验
已完成
不适用
Phase II Study of Bevacizumab in Combination with First-line Platinum-Doublet Chemotherapy in Non-squamous NSCLC Patients with Asymptomatic Untreated Brain Metastases.non-small cell lung cancerJPRN-UMIN000009828Osaka Prefectural Medical Center for Respiratory and Allergic Diseases25
已完成
2 期
Phase II Study of Bevacizumab in Combination with Carboplatin plus oral S1 in Chemo-Naive Patients with Non-Squamous Non-Small-Cell Lung CancerChemo-Naive Patients with Non-Squamous Non-Small-Cell Lung CancerJPRN-UMIN000003698Hyogo Cancer Center,Depatrment of Thoracic Oncology45
招募中
不适用
Phase II study of Bevacizumab in combination with Paclitaxel in metastatic breast cancer patients with asymptomatic brain metastases.Breast CancerJPRN-UMIN000010466Kansai medical university23
进行中（未招募）
不适用
Phase II study of Bevacizumab in combination with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. - Bevacizumab + Docetaxel-Capecitabina MammellaPatients with advanced breast cancerMedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancerEUCTR2006-003929-83-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
已完成
2 期
Phase II study of Bevacizumab in combination with FOLFIRI as second-line therapy for patients with metastatic colorectal cancer who have progressed on Bevacizumab with Oxaliplatin-based chemotherapymetastatic colorectal cancerJPRN-UMIN000002407Sapporo City General Hospital20